tiprankstipranks
Trending News
More News >
Cytek Biosciences (CTKB)
NASDAQ:CTKB
US Market

Cytek Biosciences (CTKB) Earnings Dates, Call Summary & Reports

Compare
54 Followers

Earnings Data

Report Date
Aug 12, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
-0.03
Last Year’s EPS
-0.03
Same Quarter Last Year
Based on 5 Analysts Ratings

Earnings Call Summary

Earnings Call Date:May 08, 2025
|
% Change Since: -36.15%
|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging quarter for Cytek Biosciences, with significant revenue declines in key regions like the US and EMEA. However, strong growth in service revenue, APAC markets, and recurring revenue, along with strategic product launches, provide a balanced view of both challenges and opportunities ahead.
Company Guidance
During the Cytek Biosciences First Quarter 2025 Earnings Conference Call, the company provided detailed financial guidance and performance metrics for the period. The first-quarter revenue was reported at $41.5 million, marking a 7.6% decline compared to the same period in 2024, primarily due to reduced instrument sales in the US and EMEA regions. However, service revenue increased by 24% year-over-year, reflecting strong growth driven by the expansion of the installed instrument base. Despite the revenue decline, the company expressed confidence in its strategic positioning, projecting full-year 2025 revenue to range between $196 million and $210 million, which represents a growth outlook of -2% to +5% over the previous year. The Asia Pacific region showed robust growth with a 40% increase in revenue, partly due to strong demand in China. Cytek also highlighted the expansion of its global installed base to 3,149 instruments, the launch of the FiFit Muse microsystem, and a strong focus on strategic investments in product pipeline and service teams to drive future growth. The recurring revenue from services and reagents represented 31% of total revenue, up from 26% a year ago, with a trailing twelve-month growth of 17%. The call ended with a discussion on macroeconomic challenges and market uncertainties, particularly in the academic and government sectors, which were factored into their revised revenue guidance.
Service Revenue Growth
Service revenue worldwide reached $13.3 million, an increase of 24% versus a year ago, driven by the expansion of the instrument installed base and active usage of Cytek's tools.
APAC and Rest of the World Revenue Surge
Total revenue in APAC and the rest of the world region was $11.4 million, up 35.6% year over year, with strong growth in China due to the China stimulus program.
Expansion of Cytek Cloud User Base
Cytek cloud users grew by 2,000 to over 18,000 in the first quarter, representing an average of about six users per installed Cytek FFP instrument.
Launch of FiFit Muse Microsystem
The new Muse microcell analyzer was launched, designed to enhance ease of use and precision, targeting emerging markets such as cell and gene therapy.
Recurring Revenue Growth
Trailing twelve-month recurring revenue grew 17%, now representing 31% of total revenue in the first quarter, up from 26% a year ago.

Cytek Biosciences (CTKB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CTKB Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 12, 2025
2025 (Q2)
-0.03 / -
-0.026
May 08, 2025
2025 (Q1)
-0.03 / -0.09
-0.007-1185.71% (-0.08)
Feb 27, 2025
2024 (Q4)
0.10 / 0.12
0.0934.44% (+0.03)
Nov 05, 2024
2024 (Q3)
0.01 / 0.06
-0.008887.50% (+0.07)
Aug 06, 2024
2024 (Q2)
>-0.01 / -0.03
0.014-285.71% (-0.04)
May 08, 2024
2024 (Q1)
-0.03 / >-0.01
0
Feb 28, 2024
2023 (Q4)
0.03 / 0.09
0.0650.00% (+0.03)
Nov 07, 2023
2023 (Q3)
0.02 / >-0.01
0.04-120.00% (-0.05)
Aug 08, 2023
2023 (Q2)
0.01 / 0.01
0.03-53.33% (-0.02)
May 09, 2023
2023 (Q1)
0.02 / 0.00
0.01
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CTKB Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 08, 2025
$3.79$2.92-22.96%
Feb 27, 2025
$4.81$4.49-6.65%
Nov 05, 2024
$5.44$7.40+36.03%
Aug 06, 2024
$5.62$5.09-9.43%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cytek Biosciences (CTKB) report earnings?
Cytek Biosciences (CTKB) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
    What is Cytek Biosciences (CTKB) earnings time?
    Cytek Biosciences (CTKB) earnings time is at Aug 12, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CTKB EPS forecast?
          CTKB EPS forecast for the fiscal quarter 2025 (Q2) is -0.03.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis